title: FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.
abstract: Akt is a central regulator of cell growth. Its activity can be negatively regulated by the phosphatase PHLPP that specifically dephosphorylates the hydrophobic motif of Akt (Ser473 in Akt1). However, how PHLPP is targeted to Akt is not clear. Here we show that FKBP51 (FK506-binding protein 51) acts as a scaffolding protein for Akt and PHLPP and promotes dephosphorylation of Akt. Furthermore, FKBP51 is downregulated in pancreatic cancer tissue samples and several cancer cell lines. Decreased FKBP51 expression in cancer cells results in hyperphosphorylation of Akt and decreased cell death following genotoxic stress. Overall, our findings identify FKBP51 as a negative regulator of the Akt pathway, with potentially important implications for cancer etiology and response to chemotherapy.
authors.affiliation: Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: Huadong
authors.initials: H
authors.lastname: Pei
authors.forename: Liang
authors.initials: L
authors.lastname: Li
authors.forename: Brooke L
authors.initials: BL
authors.lastname: Fridley
authors.forename: Gregory D
authors.initials: GD
authors.lastname: Jenkins
authors.forename: Krishna R
authors.initials: KR
authors.lastname: Kalari
authors.forename: Wilma
authors.initials: W
authors.lastname: Lingle
authors.forename: Gloria
authors.initials: G
authors.lastname: Petersen
authors.forename: Zhenkun
authors.initials: Z
authors.lastname: Lou
authors.forename: Liewei
authors.initials: L
authors.lastname: Wang
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002460:Cell Line; D045744:Cell Line, Tumor; D003561:Cytarabine / Q000627:therapeutic use; D000077143:Docetaxel; D004358:Drug Therapy; D006801:Humans; D007668:Kidney / Q000166:cytology; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D009687:Nuclear Proteins / Q000378:metabolism; D017239:Paclitaxel / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000378:metabolism; D010749:Phosphoprotein Phosphatases; D051057:Proto-Oncogene Proteins c-akt / Q000302:isolation & purification / Q000502:physiology*; D022021:Tacrolimus Binding Proteins / Q000378:metabolism*; D043823:Taxoids / Q000627:therapeutic use; D000099159:Tacrolimus Binding Protein 5
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D003561:Cytarabine; D000077143:Docetaxel; D009687:Nuclear Proteins; D017239:Paclitaxel; D010749:Phosphoprotein Phosphatases; D051057:Proto-Oncogene Proteins c-akt; D022021:Tacrolimus Binding Proteins; D043823:Taxoids; D000099159:Tacrolimus Binding Protein 5; C400601:PHLPP1 protein, human